MedPacto
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
MedPacto is a South Korean biotech company that develops new drugs aimed at treating hard-to-cure cancers and chronic diseases, using advanced genomic analysis to identify drug targets and biomarkers that help tailor treatments to individual patients.
Its drug candidates, including small-molecule compounds, antibodies, and Fc-fusion proteins, are designed for use in clinical and therapeutic settings. Listed on KOSDAQ, South Korea's tech-focused small-cap exchange, the company's research approach centers on combining genomic sequencing and bioinformatics tools with in-house animal-model testing to validate drug candidates.
Summary is AI-generated and may contain errors · figures from DART filings
MedPacto was spun off from Terazen Etex, a KOSDAQ-listed precision-medicine and genomics company, when its drug-research division was established as an independent entity.
MedPacto in five facts
What does MedPacto do?
MedPacto is a South Korean biotech company that develops new drugs aimed at treating hard-to-cure cancers and chronic diseases, using advanced genomic analysis to identify drug targets and biomarkers that help tailor treatments to individual patients.
Where is MedPacto listed and in which sector?
MedPacto (Korean name: 메드팩토) trades under KRX code 235980 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Industrials sector, Commercial Services.
How large is MedPacto?
Its market capitalisation was US$87.2M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were MedPacto's latest annual revenue and operating profit?
For fiscal year 2025, MedPacto reported revenue of US$2.9M, an operating loss of US$10.6M and a net loss of US$9.7M, per its annual report on DART (data retrieved from DART on 2026-09-18).
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-18
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- DisclosureOct 19
- Material management matter relevant to investment decisionsOct 2
- [Amended] DisclosureSep 18
- [Amended] DisclosureSep 18
- DisclosureSep 18
- DisclosureSep 15
- Change of 30% or more in revenue or profit/loss structure (15% for large companies)
MedPacto reported consolidated results for FY2025: revenue of US$2.67M, an operating loss of US$9.6M and a net loss of US$8.77M.
Earnings · Feb 5